Calcimax syrup

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Riboflavin; Thiamine hydrochloride; Pyridoxine hydrochloride; Ascorbic acid; Calcium pantothenate; Calcium levulinate; Calcium chloride dihydrate; Nicotinamide

Disponible depuis:

Wallace Manufacturing Chemists Ltd

Code ATC:

A11AA02

DCI (Dénomination commune internationale):

Riboflavin; Thiamine hydrochloride; Pyridoxine hydrochloride; Ascorbic acid; Calcium pantothenate; Calcium levulinate; Calcium chloride dihydrate; Nicotinamide

Dosage:

25microgram/1ml ; 100microgram/1ml ; 25microgram/1ml ; 1mg/1ml ; 25microgram/1ml ; 70mg/1ml ; 24mg/1ml ; 400microgram/1ml

forme pharmaceutique:

Oral solution

Mode d'administration:

Oral

classe:

No Controlled Drug Status

Type d'ordonnance:

Never Valid To Prescribe As A VMP

Descriptif du produit:

BNF: 09100000; GTIN: 05034593027309

Notice patient

Calcimax Syrup
_Please read this leaflet carefully before using this _
_medicine. If you have any questions or are not sure _
_about anything, ask your doctor or pharmacist. _
Calcimax Syrup has the following active ingredients
in each 5ml:
Calcium Levulinate
350.00 mg
Calcium Chloride Dihydrate BP 120.00 mg
Nicotinamide BP
2.00 mg
Riboflavine BP
0.125 mg
Thiamine Hydrochloride BP
0.50 mg
Pyridoxine Hydrochloride BP
0.125 mg
Ascorbic Acid BP
5.00 mg
Calcium Pantothenate BP
0.125 mg
In addition the syrup also contains the following non-
active ingredients: Disodium Edetate, Sucrose,
Glycine, Sodium Saccharin, Nipasept, Nipabutyl,
Propylene Glycol, Glycerin, Soluble Orange Oil,
Essence Morella Cherry, Burnt Sugar, Hydrochloric
Acid, Purified Water
Calcimax syrup is available in bottles of 150ml.
Calcimax is a dietary supplement of Calcium and
Vitamins B and C.
The product licence holder is
Wallace Manufacturing Chemists Ltd,
Wallace House, 51-53 Stert Street
Abingdon, Oxfordshire OX14 3JF, United Kingdom
Product Licence number: PL 00400/5007R
The product is manufactured for
Wallace Manufacturing Chemists Ltd by
Thorpe Laboratories Ltd,
Enterprise Road, Mablethorpe,
Lincolnshire LN12 1NB
The product is intended as a supplement of Calcium
and Vitamins B and C during periods of dietary need.
It is not intended to treat clinical deficiencies.
Do not take Calcimax Syrup if any of the following
applies to you:

You suffer from raised blood calcium levels

You have pronounced levels of calcium in your
urine

You have taken an overdose of Vitamin D

You suffer from tumours which remove calcium
from the body

You have severe kidney failure

You have kidney stones
You should seek medical advice before taking
Calcimax Syrup if you have any kidney problems.
The syrup contains sucrose and this may adversely
affect dental hygiene or control of diabetes. Calcimax
has propylene glycol as a preservative and
hypersensitivity reactions may occur in susceptible
individuals.
Calcimax Syrup may react with other foods o

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Calcimax Syrup
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5ml contains:-
Calcium Levulinate
350.00 mg
Calcium Chloride Dihydrate BP
120.00 mg
Nicotinamide BP
2.00 mg
Riboflavine BP
0.125 mg
Thiamine HCl BP
0.50 mg
Pyridoxine HCl BP
0.125 mg
Ascorbic Acid BP
5.00 mg
Calcium Pantothenate BP
0.125 mg
3.
PHARMACEUTICAL FORM
Oral Syrup
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
As a dietary supplement of Calcium and Vitamins B & C in situations of
special dietary need.
Not suitable for correction of deficiency states.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults and Elderly: Four 5ml spoonfuls twice or more times per day as
directed by a doctor.
Children: One to Two 5ml spoonfuls three times per day according to
age or
as directed by a doctor.
4.3
CONTRA-INDICATIONS
Hypercalcaemia and severe hypercalciuria, Vitamin D overdose,
decalcifying
tumours, severe renal failure, renal calculi.
4.4
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Use with caution in patients with renal impairment. The syrup contains
sucrose and this may adversely affect dental hygiene or control of
diabetes.
Calcimax has propylene glycol as a preservative and hypersensitivity
reactions
may occur in susceptible individuals.
4.5
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
High vitamin D intake should be avoided during calcium therapy unless
specially indicated. Although it is unlikely that hypercalcaemia will
result
from the administration of Calcimax, there is a risk of adverse
digoxin effects
in digitalised patients.
Oral Calcium may reduce the absorption of Tetracyclines.
Pyridoxine may antagonise effects of L-dopa unless the patient is
receiving a
peripheral Dopa-decarboxylase inhibitor.
Co-administration of thiazides increases the risk of hypercalcaemia.
4.6
PREGNANCY AND LACTATION
Epidemiological studies have shown no increase in the teratogenic
hazard to
the foetus if used in the dose recommended for usual vitamin and
calcium